ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018

Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.

Michele R Wilson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.